News

The regulator’s Oncologic Drugs Advisory Committee voted unanimously recommending approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan, to treat adult patients in three proposed indications.

The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma. MaxCyte CEO Doug Doerfler said: “The initiation of

Silence received a notice of intention to grant from the European Patent Office for patent application EP 3 222 724B, further strengthening its innovative chemical modification technology patent

Cinfa Biotech, which was founded in 2013, has offices in Munich, Germany and Pamplona, Spain. The company, which is part of Spanish pharma firm Cinfa Group, is engaged

The collaboration will leverage Jnana’s proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine’s research and development expertise in CNS disorders to advance

The trial showed that Stelara induced clinical remission in a significantly greater proportion of UC patients at week 8 compared to placebo at both doses studied. Major secondary

The Depletion of serum amyloid P component in Alzheimer’s disease (DESPIAD) trial will test whether a drug called miridesap removes a protein associated with the disease from the

Designed to Current Good Manufacturing Practices (cGMP) specifications and certified by the Belgian Federal Agency for Medicines and Healthcare Products, the new €5m facility, adjacent to its headquarters

The confirmation came from the new sub-analysis data from the Euro-Esli study of eslicarbazepine acetate for focal-onset seizures in more than 2,000 patients. Bial and Eisai said that